Dyne starts phase 3 trial of muscular dystrophy drug z-rostudirsen

May 20, 2026 7:46 AM

Dyne Therapeutics Inc. (NASDAQ: DYN) has initiated a Phase 3 clinical trial called FORZETTO to test its experimental drug z-rostudirsen ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found